

## PACKAGE LEAFLET:

### 1. Name of the veterinary medicinal product

Labimycin LA 300 mg/ml solution for injection

### 2. Composition

Each ml contains:

**Active substance:**

Oxytetracycline	300 mg
(as Oxytetracycline dihydrate)	323.18 mg)

**Excipients:**

Sodium formaldehyde sulfoxylate	4 mg
---------------------------------	------

A clear dark amber solution free from visible particles

### 3. Target species

Cattle, sheep and pigs.

### 4. Indications for use

This veterinary medicinal product is indicated for the control and treatment of a wide range of common systemic, respiratory, urinary and local infections.

**Cattle:** Treatment of respiratory infections caused by strains of *Histophilus somni*, *Mannheimia haemolytica*, *Pasteurella multocida*, *Mycoplasma bovis*.

Treatment of metritis caused by strains of *Arcanobacterium pyogenes*.

Treatment of navel/joint infections caused by strains of *Dichelobacter nodosus*, *Fusobacterium necrophorum* and *Prevotella melaninogenicus*.

**Sheep:**

Treatment of respiratory infections caused by strains of *Mannheimia haemolytica* and *Pasteurella*.

Treatment of genital infections caused by strains of *Arcanobacterium pyogenes*, *Chlamydophila spp* and *Dermatophilus congolensis*.

Treatment of navel/joint infections caused by strains of *Dichelobacter nodosus*, *Fusobacterium necrophorum* and *Prevotella melaninogenicus*.

**Pigs:**

For the treatment of respiratory infections caused by strains of *Bordetella bronchiseptica* and *Pasteurella*.

For the treatment of Erysipelas caused by strains of *Erysipelothrix rhusiopathiae*.

For the treatment of Atrophic rhinitis caused by strains of *Bordetella bronchiseptica* and *Pasteurella multocida*.

**Other infections:**

Treatment of mastitis caused by strains of *Staphylococcus aureus*, *Streptococcus agalactiae* and *Escherichia coli*.

Treatment of enzootic abortus caused by strains of *Chlamydia abortus* and *Chlamydia psittaci*.

Treatment of genital infections and Poliartthritis caused by strains of *Chlamydia abortus* and *Mycoplasma spp.*

## 5. Contraindications

Do not use in cases of hypersensitivity to the active substance(s) or to any of the excipient(s)

## 6. Special warnings

### Special precautions for safe use in the target species:

Do not dilute this veterinary medicinal product.

If administered simultaneously with other treatments, use a separate injection site.

Before any infectious process, bacteriological confirmation of the diagnosis and a sensitivity test of the bacteria causing the process is recommended.

"Use of the product should be based on identification and susceptibility testing of the target pathogen(s). If this is not possible, therapy should be based on epidemiological information and knowledge of susceptibility of the target pathogens at farm level, or at local/regional level."

"Use of the product should be in accordance with official, national and regional antimicrobial policies."

### Special precautions to be taken by the person administering the veterinary medicinal product to animals:

- The excipient dimethylacetamide may damage unborn children; therefore, women of childbearing age must be very careful to avoid exposure via spillage onto the skin or accidental self-injection when administering the product. If you are pregnant, think you may be pregnant or are attempting to conceive, you should not administer the product.
- This product may cause sensitisation.
- People with known hypersensitivity to tetracyclines, such as oxytetracycline, should avoid contact with the product.
- This product may cause skin and eye irritation.
- Avoid contact of the skin and eyes with the product. In case of accidental spillage onto skin or eyes, rinse the affected area with large amounts of water.
- Take care to avoid accidental injection. In case of self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.
- Wash hands after use

### Pregnancy and lactation:

The use is not recommended during pregnancy. The use of tetracyclines during the period of tooth and bone development, including the last part of gestation, can lead (due to their potent calcium chelating capacity) to discoloration and inhibition of bone growth."

### Interaction with other medicinal products and other forms of interaction:

Do not administer together with bactericidal antibiotics. If administered simultaneously with other treatments, should be given at different sites.

### Overdose:

Its most common effects are gastrointestinal disorders.

A double therapeutic dose in cattle can cause a severe local reaction.

### Special restrictions for use and special conditions for use:

Administration by a veterinarian surgeon or under their direct responsibility

Major incompatibilities:

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

**7. Adverse events**

Target species: Cattle, sheep and pigs.

Uncommon (1 to 10 animals / 1,000 animals treated):	Injection site reactions <sup>1</sup>
Very rare (<1 animal / 10,000 animals treated, including isolated reports):	Hypersensitivity reactions, including anaphylaxis (sometimes fatal)

\*Injection site reactions are transitory in nature

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder or the local representative of the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system {national system details}.

**8. Dosage for each species, routes and method of administration**

Intramuscular use.

The general recommended dosage for a prolonged duration of activity of 5 to 6 days is a single deep intramuscular injection of 30 mg oxytetracycline/ kg bodyweight,(equivalent to 1 ml of the veterinary medicinal product/10 kg of bodyweight)

Maximum recommended dose at one site:

Cattle:	15 ml
Sheep:	5 ml
Pigs:	10 ml
Piglets	1 day: 0.2ml
	7 days: 0.3 ml
	14 days: 0.4 ml
	21 days: 0.5 ml
	Over 21 days: 1ml/10 kg

**9. Advise on correct administration**

The rubber stopper of the vial may be safely punctured up to 50 times.  
To ensure a correct dosage body weight should be determined as accurately as possible to avoid underdosing.

**10. Withdrawal periods**

**Cattle:**

Meat and offal: 35 days  
Milk: 7 days

**Sheep:**

Meat and offal: 35 days  
Milk: 9 days

**Pigs:**

Meat and offal: 28 days

**11. Special storage precautions**

Keep out of the sight and reach of children.

Store below 25°C

Keep the vial in the outer carton in order to protect from light.

Do not use this veterinary medicinal product after the expiry date which is stated on the carton and vial after EXP. The expiry date refers to the last day of that month.

Shelf life after first opening the container: 28 days.

**12. Special precautions for disposal**

Medicines should not be disposed of in wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required.

**13. Classification of veterinary medicinal products**

Veterinary medicinal product subject to prescription.

**14. Marketing authorisation numbers and pack sizes**

Package sizes:

Box containing 1 vial of 50 ml

Box containing 1 vial of 100 ml

Box containing 1 vial of 250 ml

Box containing 12 vials of 50 ml

Box containing 10 vials of 100 ml

Box containing 10 vials of 250 ml

Not all pack sizes may be marketed.

**15. Date on which the package leaflet was last revised**

MM/YYYY

Detailed information on this veterinary medicinal product is available in the Union Product Database.

## **16. Contact details**

Marketing authorisation holder and manufacturer responsible for batch release and contact details to report suspected adverse reactions:

Labiana Life Sciences S.A. - Venus 26 - 08228 Terrassa (Barcelona) - Spain.

Local representatives:

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.